Date: Tuesday, February 10, 2026
Time: 10am - 11am ET
Services: Quantitative Systems Toxicology & Safety
Products: D360™, ToxStudio®
Summary
For toxicologists and safety pharmacologists, in vitro data offer an early warning of clinical hazards. How can we extract the most actionable intelligence from these data? The answer is three-fold: by making the interpretation of risk evidence-based, consistent across projects, and a routine part of the design-make-test-analyze cycle.
Join our to webinar to learn how scientists can detect and interpret risks from pharmacological profiling as a part of lead optimization. We’ll explain how off-target activity, direction of modulation, projected unbound exposure, and clinical precedents all inform the prediction of clinical risk at the point of discovery.
We’ll also share how to embed risk stratification into the DMTA cycle, so teams can prioritize compounds more intelligently, guide chemistry away from liabilities, and reserve in vivo studies for candidates with the highest chance of success.
Register now
David Lowis, DPhil
Executive Director of Scientific Informatics, D360For over 15 years, David has spearheaded the design and development of D360, expanding from small molecule discovery into biologics and pre-clinical research. He is a subject matter expert for D360 deployments examining scientific data workflows for discovery, preclinical, clinical and translational science.
Will Redfern, PhD
Vice President, Quantitative Systems Toxicology and SafetyWill leads the QSTS team to apply computational approaches to assess the safety of pharmaceuticals and other chemicals. He is an experienced safety pharmacologist, having worked at Syntex, Quintiles and AstraZeneca. He is a former President of the Safety Pharmacology Society.
Register now
